Bli medlem
Bli medlem

Du är här


Oxford Immunotec: Patrick J. Balthrop, Sr., Former CEO of Luminex, Joins Oxford Immunotec Board of Directors

OXFORD, United Kingdom and MARLBOROUGH, Mass., Feb. 01, 2016 (GLOBE NEWSWIRE)
-- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, commercial-stage
diagnostics company focused on developing and commercializing proprietary
tests for the management of immune-regulated conditions, today announced the
appointment of Patrick J. Balthrop, Sr. to its Board of Directors.

"Pat has been a leader in the medical technology field for over three decades
and will be a great addition to our Board," said Dr. Peter Wrighton-Smith,
Chief Executive Officer of Oxford Immunotec. "His extensive experience as a
global leader, especially within diagnostics, will be very beneficial to our
Company as we look to continue the growth of our business and drive worldwide

Most recently, Mr. Balthrop served as President and CEO of Luminex Corporation
(Nasdaq:LMNX) from 2004 to 2014, during which time the company's revenues
grew eightfold. During his tenure at Luminex, Mr. Balthrop implemented
innovative R&D programs which led to the development and subsequent
successful commercialization of a long list of new products, oversaw multiple
significant acquisitions and drove a 66% gross margin improvement. Before
joining Luminex, Mr. Balthrop served as President of Fisher Healthcare, which
is now a division of Thermo Fisher Scientific, Inc., where he was responsible
for the successful turnaround of a $1 billion integrated healthcare products
manufacturing and distribution business. Prior to that, Mr. Balthrop held
multiple positions at Abbott Laboratories, where he played an integral part
in the development and global commercialization of a number of high profile
diagnostic products. Mr. Balthrop holds an M.B.A. from the Kellogg Graduate
School of Management, Northwestern University and a B.S. from Spring Hill
College. He currently serves as a Director at Personalis and NextGxDx, as an
advisor to Water Street Healthcare Partners and Warburg Pincus, and as the
Founding Principal at Apalachee Ventures.

"I am very pleased to be joining the Oxford Immunotec Board of Directors,"
said Mr. Balthrop. "With their current portfolio of assays, and the quality
of development work underway, the Company is well positioned to grow its
leadership position in the global immunologic diagnostics industry."

About Oxford Immunotec

Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company
focused on developing and commercializing proprietary tests for the
management of immune-regulated conditions. The Company's first product is
the T-SPOT®.TB

test, which is used to test for tuberculosis infection. The T-SPOT.TB

test has been approved for sale in over 50 countries, including the United
States, where it has received pre-market approval from the Food and Drug
Administration, Europe, where it has obtained a CE mark, as well as Japan and
China. The T-SPOT.CMV

test and the T-SPOT.PRT

test are the Company's second and third products and part of a series of
products intended for the transplantation market. In addition to these three
products, the Company has additional development programs leveraging our T
cell, B cell and innate immune measuring technology. The Company is
headquartered near Oxford, U.K. and in Marlborough, Mass. Additional
information can be found at

T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd.


For Media Inquiries:

Caroline Crawley

Oxford Immunotec
Tel: +44 1235 442796

For Investor Inquiries:
Rick Altieri

Chief Financial Officer
Oxford Immunotec
Tel: +1 (508) 573-9953

Mark Klausner
Westwicke Partners
Tel: +1 (443) 213-0500


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Oxford Immunotec via Globenewswire


Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.